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Protection against deadly pathogens requires the production of high-affinity antibodies by B cells, which 
are generated in germinal centers (GCs). Alteration of the GC developmental program is common in many 
B cell malignancies. Identification of regulators of the GC response is crucial to develop targeted therapies 
for GC B cell dysfunctions, including lymphomas. The histone H3 lysine 27 methyltransferase enhancer of 
zeste homolog 2 (EZH2) is highly expressed in GC B cells and is often constitutively activated in GC-derived 
non-Hodgkin lymphomas (NHLs). The function of EZH2 in GC B cells remains largely unknown. Herein, 
we show that Ezh2 inactivation in mouse GC B cells caused profound impairment of GC responses, memory 
B cell formation, and humoral immunity. EZH2 protected GC B cells against activation-induced cytidine deam-
inase (AID) mutagenesis, facilitated cell cycle progression, and silenced plasma cell determinant and tumor 
suppressor B-lymphocyte–induced maturation protein 1 (BLIMP1). EZH2 inhibition in NHL cells induced 
BLIMP1, which impaired tumor growth. In conclusion, EZH2 sustains AID function and prevents terminal 
differentiation of GC B cells, which allows antibody diversification and affinity maturation. Dysregulation of 
the GC reaction by constitutively active EZH2 facilitates lymphomagenesis and identifies EZH2 as a possible 
therapeutic target in NHL and other GC-derived B cell diseases.
Introduction
Protective immunity against pathogens relies on the produc-
tion of high-affinity antibodies by long-lived plasma cells (PCs). 
Moreover, the ability to respond faster and with more potent anti-
bodies to subsequent encounters with the same infectious agent 
depends on the generation of long-lived memory B cells. Both, 
high-affinity memory B cells and PCs differentiate from antigen-
specific B cells that are recruited into the GC reaction during 
T cell–dependent immune responses (1). In GCs, B cells undergo 
clonal expansion, a process during which they accumulate muta-
tions at high frequency within the Ig heavy and light chain vari-
able (V) region genes. The highly dynamic nature of the GC reac-
tion is characterized by repeated cycles of cell division, Ig somatic 
mutation, and strict selection based on the ability of B cells to 
capture and present antigen to T follicular helper cells (2). These 
processes occur within distinct areas of the GC reached by B cells 
through migratory paths regulated by chemokine gradients (1). 
The molecular determinants enabling cyclic reentry of B cells into 
the proliferating and mutating compartment of centroblasts, pre-
venting terminal differentiation and the ensuing exit from the 
GC, remain poorly characterized.
Polycomb group (PcG) proteins act within 2 main polycomb 
repressive complexes (PRC1 and PRC2) to promote gene silenc-
ing. PRC1 and PRC2 catalyze posttranslational modifications of 
specific lysine residues in core histone tails, resulting in chromatin 
compaction (3). Changes in chromatin conformation regulated 
by PcG activity represent important molecular switches that con-
trol cell differentiation, proliferation, and survival in prenatal and 
postnatal life (4). Enhancer of zeste homolog 2 (EZH2) is the main 
catalytic subunit of PRC2. Through its SET domain, EZH2 catalyzes 
histone H3 lysine 27 trimethylation (H3K27me3), which is enriched 
at transcription start sites (TSSs) of repressed genes (5). Together 
with H3K4me3, H3K27me3 is found at promoters of regulators of 
lineage specification, where it acts to fine-tune their expression (6).
EZH2 is expressed at high levels in human GC B cells (7, 8). 
Moreover, whole-exome sequencing efforts have revealed that 
EZH2 gain-of-function mutations are among the most common 
genetic alterations identified in diffuse large B cell lymphoma 
(DLBCL) and follicular lymphoma originating from GC B cells 
(9, 10). Together, these results point to a critical role of EZH2 in 
GC B cell function and in the pathogenesis of GC-derived non-
Hodgkin lymphoma (NHL).
Using GC B cell–specific gene targeting in mice, we show that 
EZH2 methyltransferase activity is required to protect GC B cells 
against genotoxic damage induced by activation-induced cytidine 
deaminase (AID). Moreover, we found that EZH2 is necessary to 
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repress B-lymphocyte–induced maturation protein 1 (Blimp1) and 
Irf4 expression in GC B cells to limit terminal B cell differentiation 
induced by IL-21. Through these mechanisms, EZH2 ensures the 
persistence of B cells in the GC reaction, thus allowing the genera-
tion of high-affinity antibodies and memory B cells. We also found 
that constitutively active EZH2 is critical to stably repress tumor 
suppressor BLIMP1 expression in GC-type DLBCL cells, thereby 
possibly contributing to lymphomagenesis.
Results
Ezh2 is upregulated in mouse GC B cells. To investigate the expression 
of Ezh2 in mouse mature B cell subsets, we performed quantitative 
RT-PCR (qRT-PCR) analysis. Low Ezh2 mRNA levels were detected 
in follicular, marginal zone, and B-1 mature B cell subsets. A sub-
stantial increase in both Ezh2 transcript (Figure 1A) and protein 
(Figure 1B) levels was detected in B cells upon recruitment into 
the GC reaction during a T cell–dependent immune response. 
Within the GC, EZH2 was expressed predominantly in prolifer-
ating CXCR4+ centroblasts (Supplemental Figure 1A; supple-
mental material available online with this article; doi:10.1172/
JCI70626DS1). The differentiation of GC B cells into long-lived 
IgG1+ memory B cells or PCs coincided with lower, yet detectable, 
Ezh2 transcripts (Figure 1A). These results pointed to a role of 
EZH2 in GC B cell physiology.
Reduced number of GC B cells upon inducible Ezh2 inactivation. To 
study the specific role of EZH2 in GC B cells, conditional Ezh2 
Figure 1
EZH2 is upregulated in mouse GC B cells and required for GC formation. (A) Ezh2 transcript levels in B cell subsets relative to Rplp0. Columns 
represent mean ± SD of triplicates. Experiments were performed on pools of B cells sorted from 3 mice. (B) FACS analysis of EZH2 protein levels 
in follicular (FO) and GC B cells. Numbers indicate mean expression. (C) Representative FACS analysis of splenic B cells in NP-CGG–immunized 
Ezh2 control (Ezh2fl/+:Cγ1-cre) and mutant (Ezh2fl/fl:Cγ1-cre) mice. Numbers indicate percentage of boxed GC B cells. (D) Frequency of splenic 
GC B cells in NP-CGG–immunized Ezh2 control (Ezh2fl/+:Cγ1-cre [Ezh2+/–]; n = 17) and mutant (Ezh2fl/fl:Cγ1-cre [Ezh2–/–]; n = 22) mice. Symbols 
represent individual mice; bars refer to mean values. *P = 0.013 (t test). (E) Representative histological analysis of PNA-positive (brown) GCs 
(arrowheads) in the spleens of NP-CGG–immunized Ezh2 control (Ezh2fl/+:Cγ1-cre; n = 6) and mutant (Ezh2fl/fl:Cγ1-cre; n = 6) mice. Scale bar: 
200 μm. (F) Frequency of Ezh2 inactivation in GC B cells of Ezh2 control (Ezh2fl/+:Cγ1-cre; n = 3) and mutant (Ezh2fl/fl:Cγ1-cre; n = 4) animals, 
quantified by genomic qPCR. (G) Frequency of YFP+ GC B cells in R26-yfp;Ezh2 control (Ezh2fl/+) and mutant (Ezh2fl/fl) mice. (H) Summary of 
data on frequencies of YFP+ GC B cells in R26-yfp;Cγ1-cre;Ezh2 control (n = 4) and mutant (n = 6) mice. (F and H) Columns indicate mean ± SD. 
**P = 0.002 (t test). Data represent (C and D) 10, (G) 5, (F, and H) 3, and (B, E, and F) 2 experiments, respectively.
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knockout (Ezh2fl) mice carrying loxP sites flanking exons coding 
for the catalytic SET domain (11) were crossed with Cγ1-cre knock-
in animals expressing Cre recombinase upon onset of Ig class 
switch recombination (CSR) (12). Ezh2fl mice were also crossed 
with Cr2-cre transgenic mice to inactivate Ezh2 in all periph-
eral mature B cells (13). Ezh2fl/fl:Cγ1-cre conditional mutants and 
Ezh2fl/+:Cγ1-cre controls (hereafter referred to as controls) were 
immunized with alum-precipitated 4-hydroxy-3-nitrophenyl ace-
tyl (NP) conjugated to chicken γ globulin (CGG) to induce 
GC responses. Flow cytometry analysis revealed an aver-
age 3-fold reduction in percentages and absolute num-
bers of splenic CD19+CD38loCD95hi GC B cells in Ezh2fl/fl: 
Cγ1-cre animals, 12 to 14 days after immunization, at the 
peak of the response (Figure 1, C and D, and Supplemen-
tal Figure 1B). Histological analysis of spleen sections of 
immunized mice revealed a significant reduction in peanut 
agglutinin (PNA)–positive GCs in Ezh2 mutant animals 
(Figure 1E and Supplemental Figure 1C). Similar results 
were observed analyzing GC responses in Ezh2fl/fl:Cr2-cre 
mutants (Supplemental Figure 1D) that showed normal 
distribution and number of peripheral B cell subsets (Sup-
plemental Figure 1, E and F).
To reveal the identity of the remaining GC B cells in Ezh2fl/fl: 
Cγ1-cre animals, we determined the status of the Ezh2fl gene 
by quantitative PCR (qPCR) analysis. Whereas Cre-mediated 
recombination occurred in the majority of GC B cells in 
control animals, GC B cells of Ezh2fl/fl:Cγ1-cre mutants retained 
substantial levels of the unrecombined Ezh2fl allele (Figure 1F), 
giving rise to full-length Ezh2 transcripts (Supplemental Figure 
1G). The counter selection of Ezh2 mutant GC B cells was con-
firmed in Ezh2fl/fl:Cr2-cre mice (Supplemental Figure 1H) and in 
animals generated from crosses of Ezh2fl:Cγ1-cre mice to the R26-yfp 
Cre reporter strain. Flow cytometry analysis of splenic B cells iso-
lated from immunized mice revealed a 4- to 6-fold reduction in the 
Table 1
Mutation analysis of VH186.2 in Ezh2 control and mutant GC B cells
Genotype Mutations range Mutation frequency W33L 
 (no.) (%) (%)
Ezh2+/– 1 to 14 2.05% (54/2,637) 77.8
Ezh2–/– 1 to 8 1.06% (28/2,637) 11.1
Sequence analysis of IgH rearrangements carrying VH186.2 amplified by PCR 
from genomic DNA of Ezh2 control (Ezh2fl/+:Cγ1-cre:R26-yfp [Ezh2+/–]) and mutant 
(Ezh2fl/fl:Cγ1-cre:R26-yfp [Ezh2–/–]) GC B cells sorted on the basis of YFP expres-
sion. Mutation frequency was calculated by dividing the number of point mutations 
by the number of sequenced nucleotides. Only PCR products containing 1 or more 
mutations were analyzed. Nine unique VH186.2 sequences were analyzed for 
each genotype. Identical nucleotide substitutions present in different sequences 
were counted once if VH186.2 rearrangements shared the same CDR3 region. The 
frequency of rearrangements carrying codon 33 TGG→TTG (W33L) was counted 
by dividing the number of unique VH186.2 sequences bearing TTG substitutions 
by the total number of unique mutated VH186.2 rearrangements.
Figure 2
T cell–dependent antibody responses and memory B 
cells depend on EZH2 catalytic function in GC B cells. 
(A) NP-specific IgG1 serum titers in Ezh2 control 
(Ezh2fl/+:Cγ1-cre [Ezh2+/–]; n = 6) and mutant (Ezh2fl/fl: 
Cγ1-cre [Ezh2–/–]; n = 7) mice after primary immu-
nization with NP-CGG. Each symbol represents 1 
mouse. (B) Frequency of NP-specific IgG1+ memory 
B cells (NIP+IgG1+PNAloIgκ–CD95–CD38+CD19+) in 
the spleens of Ezh2 control (Ezh2fl/+:Cγ1-cre; n = 5) 
and mutant (Ezh2fl/fl:Cγ1-cre; n = 7) mice 60 days after 
primary NP-CGG immunization measured by FACS. 
Each symbol represents 1 mouse; bars represent 
median values. *P = 0.009 (t test). (C) NP-specific 
high-affinity (NP4) IgG1 serum titers in Ezh2 control 
(Ezh2fl/+:Cγ1-cre; n = 6; black circles) and mutant 
(Ezh2fl/fl:Cγ1-cre; n = 6; gray circles) mice at the end of 
the primary response (day 60) and 1 week after NP-
CGG boost (day 67). For the secondary response, 
4 controls and 6 Ezh2 mutant mice were used, 
respectively. (D) FACS analysis of representative 
Ezh2 control (Ezh2fl/+:Cr2-cre [Ezh2+/–]) and mutant 
(Ezh2fl/fl:Cr2-cre [Ezh2–/–]) B cell cultures at day 3 of 
LPS+IL-4 stimulation. Numbers indicate frequency of 
boxed IgG1+ B cells. Data are representative of (A–C) 
2 and (D) 5 experiments.
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percentage of YFP+ GC B cells in Ezh2fl/fl:Cγ1-cre:R26-yfp animals as 
compared with that in controls (Figure 1, G and H). The fraction 
of YFP+ GC B cells identified in Ezh2fl/fl:Cγ1-cre:R26-yfp mice was 
enriched for Ezh2 mutant alleles (Supplemental Figure 1I), indi-
cating that inactivation of the PcG protein had occurred within 
the GC. These studies reveal that EZH2 is strictly required for the 
persistence of B cells within the GC reaction.
Poor antibody responses and fewer memory B cells upon GC B cell– 
specific inactivation of Ezh2. We next investigated the effects of GC 
B cell–specific inactivation of Ezh2 on the ability of animals to 
mount an antigen-specific T cell–dependent antibody response. 
For this purpose, Ezh2fl/fl:Cγ1-cre mutants and controls were immu-
nized with NP-CGG. On average, NP-specific IgG1 titers were over 
10-fold reduced in Ezh2 mutant mice throughout the primary 
immune response (Figure 2A). The percentage of high-affinity NP-
specific IgG1+ memory B cells was also significantly reduced in the 
spleens of Ezh2fl/fl:Cγ1-cre animals 2 months after primary immu-
nization (Figure 2B and Supplemental Figure 2A). The reduction 
was already detected at the peak of the primary GC response, indi-
cating that EZH2 is necessary for the formation of IgG1 memory 
B cells (Supplemental Figure 2B).
To study the role of EZH2 in antibody affinity maturation, GC 
B cells from the spleens of NP-CGG–immunized Ezh2fl/fl:Cγ1-cre: 
R26-yfp mice were sorted on the basis of YFP expression to enrich 
for Ezh2 mutants. Mutation analysis of the VH186.2 gene expressed 
by NP-specific B cells revealed a substantial reduction in the over-
all mutation frequency in Ezh2 mutant GC B cells (Table 1). More-
over, the frequency of replacement mutations, causing a trypto-
phan-to-leucine substitution at codon 33 that confers a 10-fold 
higher affinity for NP to the BCR, was reduced in mutant GC 
B cells (Table 1). In accordance with these results, Ezh2fl/fl:Cγ1-cre 
mice showed a reduction in high-affinity NP-specific IgG1 serum 
titers in primary and recall immune responses (Figure 2C). To 
assess whether the reduction in IgG1 titers was due to a intrinsic 
defect in Ig CSR, primary B cells from Ezh2fl/fl:Cr2-cre mice were 
stimulated in vitro with LPS and IL-4. Flow cytometry analysis 
revealed a sizeable fraction of IgG1+ B cells in Ezh2 mutant cul-
tures (Figure 2D), thus excluding major defects in Ig CSR. The 
inactivation of Ezh2 in B cells was confirmed by expression of a 
truncated, catalytic-inert (EZH2ΔSET) form of the protein and by a 
reduction in global H3K27me3 levels (Supplemental Figure 2C).
Increased apoptosis of Ezh2 mutant GC B cells is independent of p19ARF 
and resistant to BCL2 overexpression. To understand the mecha-
nisms responsible for the loss of Ezh2 mutant GC B cells, Ezh2fl/fl: 
Cγ1-cre and control mice were immunized with NP-CGG and GC 
B cells were analyzed by flow cytometry for the expression of active 
caspases as a readout of apoptosis. Inactivation of Ezh2 led to a 
3-fold increase in the percentage of CaspGLOW+ apoptotic GC 
B cells (Figure 3, A and B). Similar results were observed analyzing 
GC responses in Ezh2fl/fl:Cr2-cre mice (Supplemental Figure 3A). 
Figure 3
Ezh2 inactivation increases apoptosis of GC B 
cells. (A) Representative FACS analysis of Casp-
GLOW staining of GC B cells in the spleens 
of Ezh2 control (Ezh2fl/+:Cγ1-cre [Ezh2+/–]) and 
mutant (Ezh2fl/fl:Cγ1-cre [Ezh2–/–]) mice after NP-
CGG immunization. Numbers indicate percent-
age of CaspGLOW+ cells. (B) Mean frequency 
± SD of CaspGLOW+ GC B cells in Ezh2 con-
trol (Ezh2fl/+:Cγ1-cre; n = 6) and mutant (Ezh2fl/fl: 
Cγ1-cre; n = 4) mice immunized with NP-CGG. 
**P = 0.002 (t test). (C) qRT-PCR analysis of 
Cdkn2a transcripts in purified GC B cells of Ezh2 
control (Ezh2fl/+:Cγ1-cre; n = 12) and mutant (Ezh2fl/fl: 
Cγ1-cre; n = 12) mice after NP-CGG immunization. 
Values are relative to Rplp0 expression. *P = 0.033 
(t test). (D) Frequency of splenic GC B cells in 
Ezh2 control (Ezh2fl/+:Cγ1-cre) and mutant (Ezh2fl/fl: 
Cγ1-cre) mice in the presence (Cdkn2a+/+; n = 5 
or more) or absence (Cdkn2a–/–; n = 3 or more) 
of Cdkn2a, as measured by flow cytometry after 
NP-CGG immunization. *P = 0.018; **P = 0.0017 
(t test). (E) Proportion of CaspGLOW+ splenic GC 
B cells revealed by FACS analysis in Cdkn2a-
deficient Ezh2 control (Ezh2fl/+:Cγ1-cre; n = 7) and 
mutant (Ezh2fl/fl:Cγ1-cre; n = 5) mice after NP-CGG 
immunization. (F) Efficiency of Ezh2 inactivation in 
purified splenic GC B cells of NP-CGG–immunized 
Cdkn2a-deficient Ezh2 control (Ezh2fl/+:Cγ1-cre; 
n = 2) and mutant (Ezh2fl/fl:Cγ1-cre; n = 2) mice. 
Data are representative of (A, B, and F) 2, (D and 
E) 4, and (C) 10 experiments, respectively. (C) Col-
umns indicate mean ± SEM. (D and E) Columns 
indicate mean ± SD.
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In agreement with the established role of EZH2 in the repression 
of the Cdkn2a tumor suppressor locus (14), Cdkn2a transcripts 
increased over 9 fold in Ezh2 mutant GC B cells (Figure 3C). To 
test whether the proapoptotic factor p19ARF, encoded by Cdkn2a, 
was responsible for the death of Ezh2 mutant GC B cells, we ana-
lyzed Ezh2Cdkn2a double-mutant mice (Ezh2fl/fl:Cdkn2a–/–:Cγ1-cre 
mice). Flow cytometry analysis of NP-CGG–immunized mutants 
and controls (Ezh2fl/+:Cdkn2a–/–:Cγ1-cre mice) revealed a significant 
reduction in the percentage of double-mutant GC B cells com-
pared with that in controls (Figure 3D), which was associated with 
an increased percentage of apoptotic cells (Figure 3E). Moreover, 
genomic qPCR analysis indicated the persisting counter selec-
tion of GC B cells carrying Ezh2 recombined alleles in compound 
mutants (Figure 3F). Next, we attempted to rescue apoptosis of 
Ezh2 mutant GC B cells through enforced expression of the anti-
apoptotic protein BCL2, using the EμBCL2 transgene (15). Flow 
cytometry analysis and quantitative assessment of the Ezh2fl allele 
revealed lower frequency of GC B cells, increased percentage of 
apoptotic cells, and counter selection of Ezh2 mutant GC B cells in 
compound mutants (Supplemental Figure 3, B–D). In conclusion, 
EZH2 sustains GC B cell survival independently of its repression 
of p19ARF and without limiting mitochondrial apoptosis.
Ezh2 protects GC B cells against AID-dependent genotoxic damage. 
Both in vitro and in vivo studies have provided evidence that 
PcG proteins, including EZH2, can participate in DNA damage 
responses (16–19). We thus investigated whether EZH2 protected 
Figure 4
AID induces apoptosis of Ezh2 mutant GC B cells. (A) TUNEL+ Ezh2 control (Ezh2fl/+:Cr2-cre [Ezh2+/–]; n = 3) and mutant (Ezh2fl/fl:Cr2-cre [Ezh2–/–]; 
n = 3) B cells 24 hours after IR treatment (mean frequency ± SD). (B) Proportion of Ezh2 control (Ezh2fl/+:Cr2-cre; n = 2) and mutant (Ezh2fl/fl: 
Cr2-cre; n = 2) B cells with 53BP1+ foci after exposure to IR (average frequency ± SEM). (C) Mean frequency ± SD of CaspGLOW+ Ezh2 control 
(Ezh2fl/+:Cr2-cre; n = 5) and mutant (Ezh2fl/fl:Cr2-cre; n = 7) B cells 3 days after LPS or αRP105 stimulation. (D) Histological analysis of PNA+ GC 
(blue) within IgD+ B cell follicles (brown) in the spleen of Ezh2 control (Ezh2fl/fl:Cr2-cre) and mutant (Ezh2fl/fl:Cr2-cre) mice. Scale bar: 100 μm. 
(E) Spleen GC B cell numbers in immunized Ezh2 control (Ezh2fl/+:Cr2-cre) and mutant (Ezh2fl/fl:Cr2-cre) mice before (Ezh2+/–, n = 9; Ezh2–/–, 
n = 6) and after (Ezh2+/–, n = 8; Ezh2–/–, n = 13) Aicda inactivation. Symbols represent individual mice. (F) Representative FACS analysis of 
CaspGLOW+ GC B cells in Ezh2 mutant mice (Ezh2fl/fl:Cr2-cre) before and after AID inactivation. (G) Proportion of splenic CaspGLOW+ GC B 
cells in Ezh2 control (Ezh2fl/+:Cr2-cre) and mutant (Ezh2fl/fl:Cr2-cre) mice before (Ezh2+/–, n = 7; Ezh2–/–, n = 6) and after (Ezh2+/–, n = 11; Ezh2–/–, 
n = 13) Aicda inactivation (mean ± SD). (H) Efficiency of Ezh2 inactivation in Ezh2 mutant (Ezh2fl/fl:Cr2-cre) follicular and GC B cells before 
(n = 1) or after (n = 3) Aicda inactivation. Columns indicate mean values. Data represent (E–G) 6, (H) 5, (C) 3, and (A, B, and D) 2 experiments. 
*P < 0.05; **P < 0.01; ***P < 0.0001.
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B cells from genotoxic damage through H3K27 trimethylation. 
First, we measured the response of Ezh2 mutant B cells to acute 
DNA damage induced by ionizing radiation (IR). Primary resting 
B cells purified from mutant (Ezh2fl/fl:Cr2-cre) and control (Ezh2fl/+: 
Cr2-cre) mice were stimulated in vitro with LPS and, shortly after, 
were exposed to a single dose of 0.1 and 1 Gy of IR, respectively. 
The fraction of apoptotic B cells was determined 24 hours after 
irradiation by TUNEL staining. Whereas the majority of B cells 
succumbed to 1 Gy of IR (irrespective of Ezh2 genotype), the treat-
ment with 0.1 Gy caused minor toxicity to Ezh2 proficient B cells. 
In contrast, the cultures of Ezh2 mutant B cells exposed to the 
same sublethal IR dose consisted of mostly TUNEL+ cells (Fig-
ure 4A). In accordance with this result, we found a significantly 
higher number of DNA damage response foci marked by 53BP1 
in Ezh2 mutant B cells after exposure to IR (Figure 4B). Since AID 
is a major determinant of genotoxic stress in GC B cells (20), we 
tested whether EZH2 inhibition increased the sensitivity of B cells 
to AID toxicity. Initially, we compared the behavior of Ezh2 mutant 
B cells after in vitro stimulation with either LPS/IL-4 or an anti-
body activating the Toll-like receptor homolog RP-105, as they 
differ in the ability to induce AID (Supplemental Figure 4A). Ezh2 
mutant B cells responded to both mitogenic stimuli (Supplemen-
tal Figure 4B). However, only LPS/IL-4 stimulation, which induced 
robust AID expression, caused a significant increase in apoptosis 
of Ezh2 mutant B cells and lower numbers of viable cells after 
4 days of in vitro culture (Figure 4C and Supplemental Figure 4C). 
This effect was particularly evident among IgG1 class-switched 
B cells (Supplemental Figure 4D). To directly assess the contribu-
tion of AID to the apoptosis of Ezh2 mutant GC B cells, Ezh2fl/fl: 
Cr2-cre mice were crossed with AID-deficient animals. Strikingly, 
the size of GCs and the absolute number and the percentage of GC 
B cells were largely rescued in Ezh2/Aicda double mutants (Figure 4, 
Figure 5
Genome-wide identification and characterization of H3K27me3 and H3K4me3 target genes in mouse GC B cells. (A) Venn diagram showing 
sets of genes marked by H3K27me3 and/or H3K4me3, respectively, in primary GC B cells purified from the spleens of immunized C57BL/6J 
wild-type mice. (B) Box plot of average mRNA levels of genes marked by H3K27me3 (n = 4,549), H3K4me3 (n = 6,311), or both histone marks 
(n = 1,747) in GC B cells. ***P < 2.2 × 10–16 (t test). (C) Box plot analysis of transcript levels of candidate genes (relative to Rplp0) quantified 
in Ezh2 control (Ezh2fl/+:Cγ1-cre [Ezh2+/–]; n = 15) and mutant (Ezh2fl/fl:Cγ1-cre [Ezh2–/–]; n = 17) primary GC B cells. P values are indicated 
within each plot (Wilcoxon rank-sum test). (B and C) In box-and-whisker plots, horizontal bars indicate the medians, boxes indicate 25th to 75th 
percentiles, and whiskers indicate one and half time the value of the interquartile range added to the 75th percentile, or subtracted to the 25th 
percentile, respectively. (D) H3K27me3 status in wild-type GC B cells of 67 candidate genes (listed in Supplemental Table 2) tested by qRT-PCR 
in Ezh2 control and mutant GC B cells described in C. The genes were grouped based on whether expression was upregulated (up) or remained 
unchanged (no change) in Ezh2 mutant GC B cells. ***P = 0.0009 (Fisher’s exact test).
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D and E, and Supplemental Figure 4, E and F). Importantly, AID 
inactivation led to the normalization of apoptosis of Ezh2 mutant 
GC B cells (Figure 4, F and G), allowing for the first time efficient 
recovery of cells that had recombined both Ezh2fl alleles (Figure 
4H). These results show that EZH2 protects against DNA dam-
age–induced apoptosis, in particular, in GC B cells, genotoxicity 
linked to AID mutagenesis.
Ezh2 regulates the GC B cell transcriptional program. Despite the con-
sistent normalization of apoptosis, Ezh2fl/fl:Aicda–/–:Cr2-cre com-
pound mutants showed still a modest, yet reproducible, reduction 
in GC B cell numbers and, in few cases, Ezh2/Aicda double-mutant 
GC B cells remained counter selected (Supplemental Figure 4G). 
These results suggested additional function(s) of Ezh2 in GC B cells. 
To address this, we performed H3K27me3 ChIP assays coupled to 
high-throughput sequencing (ChIP-seq) to identify Ezh2 target 
genes in GC B cells at a genome-wide level. We used the model- 
based analysis of ChIP-seq peak calling software and applied a 
stringent P value (P < 10 × 10–10) cutoff for peak detection that 
we recently validated to uncover the core subset of polycomb tar-
gets in somatic cell reprogramming (21). A similar approach was 
used for global identification of targets of H3K4me3 that marks 
actively transcribed loci. In GC B cells, we identified 7,404 genes 
that carried H3K27me3 in a 10-Kb genomic interval centered on 
the TSS. Of these targets, 41% (3,082 out of 7,404 genes) carried 
the H3K4me3 mark also, thus representing bivalent genes (Figure 
5A and Supplemental Table 1). Instead, 7,436 genes were exclu-
sively marked by H3K4me3 (Figure 5A and Supplemental Table 1). 
To gain insights into the biological function of H3K27me3 tar-
gets in GC B cells, we performed a Gene Ontology analysis. Genes 
marked by H3K27me3 were significantly (P ≤ 0.01) enriched for 
categories involved in developmental processes (Supplemen-
tal Figure 5A), whereas H3K4me3 preferentially marked genes 
involved in metabolism (Supplemental Figure 5B). To understand 
the influence of H3K27me3 on target gene expression, we com-
pared the average transcript levels of genes marked in GC B cells, 
by H3K27me3, H3K4me3, or by both, respectively. In accordance 
with previous observations (22), we found that genes marked by 
H3K27me3 were significantly (P < 2.2 × 10–16) less transcribed than 
those marked by H3K4me3 (Figure 5B). Transcripts encoded by 
bivalent genes showed intermediate levels, which were significantly 
lower (P < 2.2 × 10–16) than those derived from H3K4me3-marked 
genes (Figure 5B). These data pointed to a role for EZH2 in tran-
scriptional silencing of target genes in GC B cells. To test this, we 
quantified the transcript levels of a representative set of genes in 
Ezh2 mutant and control GC B cells (n = 67) selected according to 
H3K27me3 status and relevance in B cell biology (Supplemental 
Table 2). We found that differentially expressed genes (P < 0.05) were 
all upregulated in Ezh2 mutant GC B cells (Figure 5C) and prefer-
entially marked by H3K27me3 in Ezh2-proficient GC B cells (Figure 
5D and Supplemental Figure 5C). These included key regulators of 
cell cycle progression (Cdkn1a, Cdkn1b, and Cdkn2a) and GC B cell 
differentiation (Id2, Blimp1, Irf4, and Xbp1; Figure 5C). For IRF4, 
we confirmed the upregulation at the protein level. Moreover, the 
fraction of cells expressing high IRF4 levels increased significantly 
Figure 6
EZH2 regulates G1-to-S transition in B cells in a p16INK4A-independent fashion. (A) Representative cell cycle analysis of day 4 Ezh2 control 
(Ezh2fl/+:Cγ1-cre [Ezh2+/–]; n = 3) and mutant (Ezh2fl/fl:Cγ1-cre [Ezh2–/–]; n = 4) iGB cells stained with propidium iodide (PI) and pulsed with EdU 
1 hour prior to analysis. Numbers indicate percentage of cells in G0/G1 (bottom left), S (top), and G2/M (bottom right) phase of the cell cycle, 
respectively. (B) Summary of data on cell cycle distribution of Ezh2 control (Ezh2fl/+:Cγ1-cre; n = 3) and mutant (Ezh2fl/fl:Cγ1-cre; n = 4) iGB cells 
at day 4 of stimulation. (C) Transcript levels of cyclin-dependent kinase inhibitors in Ezh2 mutant (Ezh2fl/fl:Cγ1-cre) iGB cells relative to control 
(Ezh2fl/+:Cγ1-cre) and Rplp0. Expression of p19ARF encoded by Cdkn2a was also assessed. Columns represent mean ± SEM. (D) Summary data 
on cell cycle distribution of Ckn2a-deficient Ezh2 control (Ezh2fl/+:Cγ1-cre; n = 3) and mutant (Ezh2fl/fl:Cγ1-cre; n = 3) iGB cells at day 4 of stimula-
tion. (B and D) Columns indicate mean ± SD. *P = 0.009; **P = 0.001 (t test).
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in GCs of Ezh2 conditional mutants (Supplemental Figure 6, A 
and B). Instead, the expression of H3K4me3-only targets remained 
largely unaffected in response to Ezh2 inactivation (data not 
shown). Collectively, these data assign a critical control over cell 
cycle progression and differentiation of GC B cells to EZH2.
Ezh2 facilitates B cell proliferation independent of repression of CDK 
inhibitors. The identification of Cdkn1a, Cdkn1b, Cdkn2a as targets 
of H3K27me3 in GC B cells pointed to a role for EZH2 in the 
regulation of cell cycle progression, possibly through the repres-
sion of CDK inhibitors (8, 23). To test this hypothesis, given the 
difficulty in tracking the few Ezh2 mutant GC B cells in vivo, we 
performed cell cycle distribution analysis after in vitro activation 
of Ezh2 mutant B cells with membrane-bound CD40L and IL-4. 
Acute EZH2 inactivation in B cells led to an accumulation of cells 
in the G0/G1 phase of the cell cycle (Figure 6, A and B). Expression 
analysis revealed a substantial upregulation of the CDK inhibitor 
p16Ink4a in Ezh2 mutant B cells (Figure 6C). To determine whether 
induction of p16Ink4a was responsible for the defect in G1-to-S 
transition of Ezh2 mutant B cells, we analyzed the cell cycle profile 
of Ezh2/Cdkn2a double-mutant B cells after CD40L/IL-4 stimula-
tion. In contrast to previous results (24, 25), Cdkn2a inactivation 
failed to normalize the cell cycle profile of Ezh2 mutant B cells 
(Figure 6D). Moreover, expression of other CDK inhibitors was 
largely unaffected in Ezh2 mutant primary B cells after mitogenic 
stimulation, excluding their possible involvement in the cell cycle 
defect (Figure 6C). All together these results unravel a novel mech-
anism that uncouples EZH2 control of G1-to-S transition from the 
repression of CDK inhibitors.
Ezh2 is required for repression of a subset of BCL6 targets in GC B cells. 
We noticed that several genes upregulated in Ezh2 mutant GC 
B cells are bound with high significance and repressed by the tran-
scriptional repressor BCL6 in GC B cells (26). Given the relevance 
of BCL6 in the regulation of the GC reaction (27), we investigated 
the influence of EZH2 on BCL6-dependent gene silencing. Spe-
cifically, we quantified the transcript levels of 49 highly significant 
(false discovery rate [FDR] ≤ 0.0001) BCL6 targets in Ezh2 mutant 
GC B cells (27). Of these, around one-third (n = 16) were marked 
by H3K27me3 in wild-type GC B cells (Supplemental Table 3). 
Whereas expression of BCL6 targets lacking H3K27me3 remained 
largely unaltered by Ezh2 inactivation (3 out of 33 genes), nearly 
half of the genes bound by PRC2 and BCL6 in wild-type GC 
B cells (7 out of 16 genes; Bcl2, Id2, Cdkn1b, Cdkn2a, Myb, Blimp1, 
and Irf4) were upregulated in the Ezh2 mutant counterparts (Fig-
ure 5C, Figure 7A, and Supplemental Table 3). To exclude that 
EZH2 regulated the BCL6 gene, we crossed conditional Ezh2 
mutant mice (Ezh2fl/fl:Cγ1-cre mice) with IμHABCL6 knockin ani-
Figure 7
EZH2 modulates BCL6 repression in GC B cells. (A) Percentage of a representative set of BCL6 target genes (FDR ≤ 0.0001; Supplemental Table 3) 
that are significantly (P < 0.05) upregulated in Ezh2 mutant GC B cells, classified on the basis of H3K27me3 status in their wild-type counterparts. 
**P = 0.004 (Fisher’s exact test). (B) Box plot representation of transcript levels (relative to Rplp0) of a representative set of BCL6 target genes 
in Ezh2 control (Ezh2fl/+:Cγ1-cre [Ezh2+/–]; n = 11, white) and mutant (Ezh2fl/fl:Cγ1-cre [Ezh2–/–]) GC B cells, respectively. Ezh2 mutant GC B cells 
were compared before (n = 14, gray) and after (n = 3, blue) complementation with the IμHABCL6 transgene. Significance of the differences in 
gene expression levels is indicated within each plot (Wilcoxon rank-sum test). Horizontal bars indicate the medians, In box-and-whisker plots, 
horizontal bars indicate the medians, boxes indicate 25th to 75th percentiles, and whiskers indicate one and half time the value of the interquartile 
range added to the 75th percentile, or subtracted to the 25th percentile, respectively.
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mals expressing BCL6 under the Iμ promoter that is constitutively 
active in B cells (28). Expression analysis performed on primary GC 
B cells of compound mutants revealed the failure of IμHABCL6 to 
normalize expression of a subset of H3K27me3/BCL6 shared tar-
gets (Figure 7B). These results indicate that EZH2 regulates BCL6 
repressor function on a subset of common targets in GC B cells.
H3K27me3 marking of Blimp1 and Irf4 in GC B cells is erased upon 
induction of PC differentiation. Bioinformatic analysis of ChIP-
seq data identified the PC determinant Blimp1 as a target of 
H3K27me3 in mouse GC B cells, in accordance with recent find-
ings in the human counterparts (23). We confirmed this result 
by performing H3K27me3 ChIP-qPCR analyses on primary GC 
B cells (Figure 8A) and A20 and I.29μ+ murine B lymphoma cells 
(Supplemental Figure 7A) expressing low levels of Blimp1 (Sup-
plemental Figure 7F). Accordingly, the PRC2 core component 
Suz12 was recruited to the Blimp1 locus in BLIMP-negative B cells 
(Supplemental Figure 7B). In a similar fashion, screening by ChIP-
qPCR identified H3K27me3 deposition in a region proximal to the 
Irf4 TSS in primary GC B cells and A20 and I.29μ+ lymphoma cells 
(Figure 8A and Supplemental Figure 7A). These results establish 
that Blimp1 and Irf4 are direct targets of PRC2 in GC B cells.
To study the regulation of H3K27 trimethylation at the Blimp1 
and Irf4 loci during terminal differentiation, we stimulated B cells 
in vitro with either LPS or IL-21. A substantial loss of H3K27me3 
at the Blimp1 and Irf4 loci (Figure 8B) was detected within the first 
24–48 hours after stimulation. In particular, for Irf4, this coincided 
with loss of Suz12 binding, increased H3K4 trimethylation, and 
recruitment of RNA polymerase II to the promoter, which correlated 
Figure 8
H3K27me3 marks Blimp1 and Irf4 in GC B cells and restricts PC differentiation. (A) Blimp1 and Irf4 H3K27me3 ChIP-qPCR in primary GC 
B cells. Gapdh was assessed as negative control. Enrichment is relative to input and histone H3 density. Columns represent mean values. (B) 
Blimp1 and Irf4 H3K27me3 ChIP-qPCR in I.29μ+ B cells before (–) and 48 hours after LPS stimulation and in A20 cells in response to 24 hours of 
IL-21 stimulation. (C) Immunoblot analysis of H3K27me3 and full-length (Ezh2)/truncated (Ezh2SET) EZH2 levels in representative Ezh2 control 
(Ezh2fl/+:Cγ1-cre [Ezh2+/–]; n = 3) and mutant (Ezh2fl/fl:Cγ1-cre [Ezh2–/–]; n = 3) iGB cultures 4 days after CD40L/BAFF/IL-4 stimulation. Histone H3 
was assessed as loading control. Quantification of H3K27me3 levels relative to controls is shown. (D) Blimp1 and Irf4 H3K27me3 ChIP-qPCR 
analysis in Ezh2 control (Ezh2fl/+:Cγ1-cre) and mutant ( Ezh2fl/fl:Cγ1-cre) iGB cells stimulated as in C. (E) qRT-PCR analysis of Irf4 and Blimp1 
transcripts in Ezh2 control (Ezh2fl/+:Cγ1-cre; n = 3) and mutant (Ezh2–/–; Ezh2fl/fl:Cγ1-cre; n = 4) iGB cells stimulated as in C. Values are relative to 
Rplp0. Columns indicate mean ± SEM. *P = 0.006 (t test). (F) Representative FACS analysis and (G) frequency of Irf4hiCD138+ PCs in control 
(Ezh2fl/+:Cγ1-cre; n = 6) and mutant (Ezh2–/–; Ezh2fl/fl:Cγ1-cre; n = 6) iGB cultures 2 days after IL-21 stimulation. ***P = 0.0006 (t test). (H) IgG1 
levels in the supernatant of Ezh2 control (Ezh2fl/+:Cγ1-cre; n = 3) and mutant (Ezh2–/–; Ezh2fl/fl:Cγ1-cre; n = 3) iGB cultures after IL-21 stimulation. 
(G and H) Symbols represent individual samples; bars refer to mean values. (B and D) Fold enrichments are calculated as in A.
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with augmented Irf4 transcription (Supplemental Figure 7, C–E). 
Notably, induction of PC differentiation did not promote global 
H3K27 demethylation, as PRC2 targets Hoxa9 and Olig1 remained 
marked by H3K27me3 and bound by Suz12 in stimulated B cells 
(Supplemental Figure 7G). These results reveal that Blimp1 and Irf4 
upregulation during onset of PC differentiation is accompanied by 
a substantial loss of H3K27me3 proximal to their TSS.
Ezh2 restricts terminal B cell differentiation promoted by IL-21. To assess 
the relevance of EZH2-dependent repression of Blimp1 and Irf4 in 
GC B cells, we determined the effects of acute Ezh2 inactivation 
on terminal differentiation. Primary Ezh2fl/fl:Cγ1-cre B cells were 
stimulated in vitro for 4 days with CD40L, BAFF, and IL-4 to gen-
erate proliferating GC-like B cells (also called iGB cells; ref. 29) that 
were ultimately differentiated into PCs by the addition of IL-21 to 
the culture media (29). Efficient Ezh2 inactivation in iGB cells led 
to a substantial reduction in global H3K27me3 levels (Figure 8C) 
that was confirmed at the Blimp1 and Irf4 loci by ChIP-qPCR analy-
sis (Figure 8D). Ezh2 mutant iGB cells expressed higher Irf4 and 
Blimp1 transcript levels (Figure 8E), which was alone sufficient to 
trigger differentiation of a subset of CD40-activated B cells into 
Irf4hiCD138+ PCs (Supplemental Figure 8A). Importantly, upon 
IL-21 stimulation, over one-third of Ezh2 mutant iGB cells differ-
entiated into Irf4hiCD138+ PCs, significantly outnumbering those 
present in control cultures (Figure 8, F and G). In accordance with 
this result, conditioned media of Ezh2 mutant iGB cultures stimu-
lated with IL-21 contained higher levels of soluble IgG1 antibodies 
(Figure 8H), which coincided with a greater number of IgG1+ anti-
body-secreting cells, when compared with controls (Supplemental 
Figure 8B). These results indicate that EZH2 repression of Blimp1 
and Irf4 restricts IL-21–controlled PC differentiation.
Y641 mutant of EZH2 enforces BLIMP1 repression to support DLBCL 
growth. BLIMP1 has been proposed tumor suppressor since 
its inactivation occurs frequently in human DLBCL and pro-
motes B cell lymphomas in mouse models (30–32). In DLBCL, 
impaired BLIMP1 expression results from genetic alterations 
of the BLIMP1 locus or stable repression by BCL6 (32). BLIMP1 
mutations have been almost exclusively associated with ABC-type 
DLBCL (30, 32). Since EZH2 gain-of-function mutations occur 
predominantly in GC-type DLBCL (9) and given that Blimp1 is 
a direct target of EZH2 repression in primary mouse GC B cells, 
we investigated whether EZH2 was required for stable BLIMP1 
silencing in GC-type DLBCL. To this aim, we treated the DLBCL 
cells lines, SU-DHL-4 and SU-DHL-6, expressing constitutive-
ly active forms of EZH2 (9, 33) with the EZH2 small molecule 
inhibitor, GSK343 (34). Treatment of tumor cells with 2.5 μM 
GSK343 led to a reduction in global levels of H3K27me3, with-
out interfering with EZH2 expression (Supplemental Figure 9, 
A and B). Importantly, exposure of DLBCL cells to GSK343 
induced a substantial upregulation of BLIMP1 expression in 
both DLBCL lines (Figure 9A). This effect was associated with 
impaired in vitro lymphoma growth (Figure 9B) that was con-
tributed by a partial arrest in cell cycle progression at the G1-to-S 
Figure 9
Y641 mutant of EZH2 silences BLIMP1 expres-
sion through PRC2 to facilitate DLBCL growth. 
(A) BLIMP1 transcripts in SU-DHL-4 and SU-
DHL-6 DLBCL cells 12 days after treatment 
with GSK343 or vehicle, as revealed by qRT-
PCR analysis. Columns indicate mean ± SD 
of triplicates. Expression is relative to that of 
vehicle-treated control cells after normalization 
for RPLP0 expression. (B) Growth curves of 
SU-DHL-4 (black line) and SU-DHL-6 (gray line) 
DLBCL cells treated with either GSK343 (solid 
line) or vehicle (dotted line). Average cell num-
bers at the indicated time points ± SEM of 4 rep-
licates is shown. ***P < 0.001 (2-way ANOVA). 
(C) BLIMP1 transcript levels in SU-DHL-4 
DLBCL cells after infection with lentiviruses 
expressing control (ctrl) or anti-EED (EED) 
shRNAs, respectively. Results are presented 
relative to control after normalization for GAPDH 
expression. Columns indicate mean of 2 inde-
pendent experiments. (D) Frequency of SU-
DHL-4 DLBCL cells expressing shRNA against 
EED relative to those expressing control shRNA 
at the indicated days after lentivirus infection. (E) 
qRT-PCR analysis of Blimp1 transcript levels in 
WSU-DLCL-2 DLBCL cells transfected with con-
trol or BLIMP1 expression vector, respectively. 
Columns indicate mean value of 2 independent 
experiments. Values are presented relative to 
control after normalization for HPRT expression. 
(F) Comparison of WSU-DLCL-2 cell numbers 
at the indicated days after transfection with con-
trol or Blimp1 expression vector, respectively. 
Data are representative of 2 experiments.
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regulation of the GC B cell transcriptional program. H3K27me3 
targets were preferentially repressed in GC B cells and strongly 
enriched for developmental regulators, supporting the notion 
that, in differentiated cells, PRC2 has a critical function to preserve 
silencing of transcriptional programs driving alternative cell fates. 
Importantly, EZH2 also exerted a direct control of the expression 
of a substantial number of genes that regulate the persistence and 
expansion of B cells within the GC reaction. EZH2 was required 
to repress Id2, the inhibitor of the E-box protein E2A, whose func-
tion is necessary for GC B cells (42). In GC B cells, EZH2 was also 
critical to prevent the expression of the cyclin-dependent kinase 
inhibitor p16INK4A encoded by the Cdkn2a locus, which regulates 
G1-to-S transition. In accordance with this, a higher proportion 
of Ezh2 mutant cells was arrested at the G0/G1 stage after CD40 
stimulation. Surprisingly, in contrast to previous reports, the cell 
cycle defect was neither rescued by Cdkn2a inactivation nor asso-
ciated with substantial changes in the expression of other CDK 
inhibitors. These results unravel a novel mechanism through 
which EZH2 facilitates G1-to-S progression that is independent 
of CDK repression.
Of note, the majority of H3K27me3 targets that we found 
upregulated in Ezh2 mutant GC B cells are bound and repressed 
by BCL6 (26), which is essential for GC B cell function (27). This 
result underscores a possible cooperation between PRC2 and BCL6 
in the repression of common targets, which include important 
negative regulators of GC B cell function, such as Id2 and Blimp1. 
Our data support a scenario in which EZH2 primarily regulates 
BCL6 repressor activity, as enforced BCL6 expression was not suf-
ficient in Ezh2 mutant GC B cells to restore repression of a repre-
sentative subset of shared targets.
One of the main findings of this study is the identification of 
PC determinants Blimp1 and Irf4 (43–45) as direct targets of EZH2 
repression in GC B cells. Blimp1 and Irf4 genes were marked by 
H3K27me3 and bound by PRC2 in B cells prior to onset of PC 
differentiation. This regulation was critical to repress Blimp1 and 
Irf4, since transcripts for both PC determinants were significantly 
upregulated in Ezh2 mutant GC B cells. The induction of the PC 
program in GC B cells following EZH2 inhibition was completed 
by the upregulation of Xbp1, which is required to sustain high 
rates of Ig synthesis (46, 47). Acute Ezh2 inactivation was sufficient 
to trigger terminal differentiation of a subset of CD40-activated 
B cells. More strikingly, the addition of IL-21 substantial boosted 
differentiation of PcG mutant B cells into antibody-secreting cells 
in response to CD40 stimulation. This result indicates that EZH2 
limits the amplitude of the PC response induced by IL-21 (48), 
thereby possibly extending the persistence of B cells in the GC 
(49, 50). We propose that, in GC B cells, EZH2 modulates IL-21–
dependent Blimp1 expression via H3K27 trimethylation (51, 52). 
Therefore, signals regulating PRC2 recruitment at the Blimp1 locus 
are predicted to influence the balance between IL-21–dependent 
Bcl6 and Blimp1 expression and, thereby, the decision of B cells to 
persist rather than exit from the GC reaction. The control of Irf4 
expression exerted through H3K27me3 is likely to contribute to 
the regulation by EZH2 of the fate of GC B cells (53).
The increased susceptibility of Ezh2 mutant B cells to PC dif-
ferentiation is seemingly in contrast with reduced serum Ig titers 
measured in PcG mutant animals after immunization with T cell– 
dependent antigens. The increased apoptosis may represent a 
major obstacle for Ezh2 mutant B cells to exit the GC as antibody-
secreting cells. Moreover, whereas EZH2 inactivation interferes 
transition (Supplemental Figure 9C). To understand wheth-
er Y641 mutant of EZH2 exerted its catalytic activity within 
PRC2, we inhibited the expression of the essential PRC2 sub-
unit EED in DLBCL cells. Downregulation of EED in SU-DHL-4 
cells (Supplemental Figure 9, D and E) caused a global reduc-
tion in H3K27me3 levels (Supplemental Figure 9F) and, most 
importantly, a substantial upregulation of BLIMP1 expression 
(Figure 9C). Similar results were obtained in A20 lymphoma 
B cells expressing wild-type EZH2 (Supplemental Figure 10). 
Inhibition of EED interfered with in vitro DLBCL growth (Figure 
9D) and impaired cell cycle progression (Supplemental Figure 
9G), extending our data as well as that of others based on the 
use of EZH2 small molecule inhibitors (23, 35–37). In a subset of 
SU-DHL-4 cells, PRC2 inhibition alone was sufficient to cause 
the induction of surface CD138 expression and the downregu-
lation of MHC class II molecules, which accompanies terminal 
differentiation (Supplemental Figure 9H). To test whether induc-
tion of BLIMP1 was alone sufficient to influence growth of B lym-
phoma cells expressing a constitutively active form of EZH2, we 
complemented WSU-DLCL-2 DLBCL cells with a BLIMP1 expres-
sion vector. Transient expression of BLIMP1 (Figure 9E) caused a 
severe impairment in in vitro growth of DLBCL, which ultimately 
led to fewer lymphoma cells retrieved 2 days after complementa-
tion (Figure 9F). All together, these results indicate that consti-
tutively active EZH2 represses the tumor suppressor BLIMP1 via 
PRC2 to facilitate the growth of GC-type DLBCL.
Discussion
The strong induction of EZH2 in GC B cells, combined with the 
frequent occurrence of EZH2 gain-of function mutations in GC-
derived NHL, suggested a role for the PcG protein in the regula-
tion of the GC reaction. Indeed, using cell type–specific gene tar-
geting in mice, we show that Ezh2 methyltransferase activity is 
strictly required for GC B cell function. EZH2 inactivation resulted 
in fewer GCs, reduced numbers of high-affinity long-lived memory 
B cells, and impaired production of antigen-specific antibodies 
upon encounter with T cell–dependent antigens.
The failure to sustain the GC reaction was largely contributed 
by enhanced apoptosis of Ezh2 mutant B cells, which was inde-
pendent of p19ARF upregulation and resistant to constitutive BCL2 
expression. Strikingly, instead, GC B cells lacking functional EZH2 
became highly vulnerable to genotoxic stress associated with AID 
function. As a consequence of premature death, Ezh2 mutant GC 
B cells carried fewer Ig V gene mutations and failed to be selected 
by antigen-driven selection. The enrichment for apoptotic cells 
among Ig class-switched Ezh2 mutant B cells suggests a possible 
contribution of the PcG protein to the repair of DNA breaks gen-
erated during IgH isotype switching, extending previous findings 
(16, 18, 19, 38). In support of this, Ezh2 mutant primary B cells 
displayed higher numbers of DNA damage foci marked by 53BP1 
after exposure to a sublethal dose of IR. The failure of Ezh2 mutant 
GC B cells to preserve genome integrity may trigger ultimately 
their death, possibly as a consequence of mitotic catastrophe. This 
scenario does not exclude that EZH2 may act to limit the genome-
wide recruitment of AID via H3K27me3-dependent silencing of 
target genes (39, 40). Future studies will establish whether EZH2 
inactivation increases the frequency of off-target mutations 
caused by AID, in particular at bivalent genes (40, 41).
Global identification of H3K27me3 targets combined with 
expression analyses revealed a critical contribution of EZH2 to the 
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(C36B11; Cell Signaling), or EZH2-specific (AE25.13; K. Helin, University 
of Copenhagen, Copenhagen, Denmark) mAb conjugated in house with 
Alexa Fluor dyes according to manufacturer’s instructions (Molecular 
Probes, Invitrogen). Samples were acquired on a FACSCalibur (BD Biosci-
ences), and data were analyzed with FlowJo software (Tree Star).
Immunoblotting analysis. Immunoblotting analyses were performed with anti-
bodies specific for EZH2 (AE25-13; K. Helin), H3K27me3 (07-449; Upstate), 
histone H3 (07-690; Millipore), and EED (AA19-30; K. Helin), respectively. 
Immunoblot images were acquired using the ChemiDoc system (Bio-Rad).
Analysis of apoptosis and DNA damage. GC B cell apoptosis was measured 
with the CaspGLOW Staining Kit (BioVision). Irradiation was performed 
using a Faxitron (X-Ray Corporation) on MACS-purified primary B cells 
stimulated in vitro for 48 hours with 20 μg/ml LPS. TUNEL staining was 
performed using the In situ Cell Death Detection Kit (Roche) following 
the manufacturer’s instructions. Cells were acquired on a FACSCalibur 
(BD Biosciences), and data were analyzed with FlowJo software (Tree 
Star). 53BP1+ DNA damage foci were quantified in LPS-activated primary 
B cells 2.5 hours after exposure to 0.2 Gy of IR. To detect 53BP1+ foci, cells 
were fixed in PBS/4% paraformaldehyde, permeabilized, and stained with 
53BP1-specific antibody (Novus Biologicals, NB100-304), and foci were 
visualized with a fluorescent-labeled secondary antibody in combination 
with DAPI staining. Photographs were acquired using an upright fluores-
cence microscope (Olympus AX-70; ×40 magnification). Cells with 2 or 
more 53BP1+ foci were counted.
Cell cycle analysis. iGB cells were pulsed with EdU (44 μM; Invitrogen) for 
1 hour followed by EdU measurement using the Click-iTEdU Alexa Fluor 
647 Flow Cytometry Assay kit according to the manufacturer’s instruc-
tions (Invitrogen). DLBCL were labeled with BrdU (33 μM; Sigma-Aldrich) 
for 1 hour followed by determination of BrdU according to manufactur-
er’s instructions (BD Pharmingen). Samples were stained with propidium 
iodide, acquired on a FACSCalibur (BD Biosciences), and analyzed using 
FlowJo software (Tree Star).
ELISA. To quantify NP-specific serum antibodies, plates were coated 
with 2 μg/ml NP23-BSA or NP4-BSA, respectively (Biosearch Technolo-
gies), and bound were antibodies detected with biotin-conjugated anti-
IgM (R33.24.12) or anti-IgG1 (550331; BD Pharmingen) antibodies. IgG1 
levels in conditioned media of iGB cultures were measured using a com-
bination of rat anti-mouse IgG1 antibodies (MCA1289 [ABD Serotec] and 
A85-1 [BD Pharmingen]).
ELISPOT. MultiScreen HTS-HA filter plates (MSHAS4510; Millipore) 
were coated with 1 μg rat anti-mouse IgG1 (LO.MG1-13; ABD Serotec). 
Cells were seeded for 6 hours at 37°C, and bound IgG1 antibodies were 
detected with biotinylated rat anti-mouse IgG1 (A85-1; BD Pharmingen) 
followed by streptavidin coupled to alkaline phosphatase (ELIspot Kit; 
R&D Systems). Images of plates were acquired, and the number of spots 
was scored using ImageJ software.
qPCR analysis. qRT-PCR was performed in triplicate with SYBR Green-I 
Master Mix using primer combinations listed in Supplemental Table 4 or 
using custom-made TaqMan Array Micro Fluidic Cards (Applied Biosys-
tems). Probe sets are listed in Supplemental Table 4. Expression values were 
calculated as 2–Δct. Ezh2 gene copy number was quantified by qPCR using 
primers annealing to genomic DNA lying within the loxP-flanked segment 
(Supplemental Table 4). Values were calculated using the comparative 
CT method. To normalize for DNA input, a segment of the Gapdh gene was 
amplified using primers listed in Supplemental Table 4.
Ig VH gene mutation analysis. Ig rearrangements bearing the VH186.2 gene 
were analyzed as described previously (61). PCR primers are listed in 
Supplemental Table 4.
Histology. Snap-frozen spleens were embedded in Cryo-M-Bed (Bright 
Instruments). Sections mounted onto multispot glass slides (Hendley) 
neither with Blimp1-controlled Xbp1 expression nor with the 
establishment of the transcriptional program that supports the 
unfolded protein response (short-lived Ezh2 mutant PCs secrete 
normal amounts of antibodies in vitro), additional experiments 
will be required to determine whether EZH2 is required for long-
term PC persistence (54).
The identification of Blimp1 as a direct target of EZH2 is relevant 
for the understanding of the mechanisms through which the PcG 
protein may contribute to the pathogenesis of DLBCL. BLIMP1 
loss-of-function mutations occur frequently in ABC-type DLBCL 
and accelerate lymphomagenesis in mouse models, supporting its 
role as tumor suppressor (30–32). The rare occurrence of BLIMP1 
mutations in GC-type DLBCL suggests the existence of additional 
mechanisms that could prevent its expression in this form of NHL. 
Using pharmacological inhibition of EZH2 and functional inac-
tivation of PRC2, we provide evidence that constitutively active 
EZH2 enforces BLIMP1 silencing in GC-type DLBCL cells. While 
our manuscript was under review an independent study reached 
similar conclusions (23). Importantly, we provide evidence that 
BLIMP1 induction alone is sufficient to impair in vitro growth of 
GC-type DLBCL expressing mutant EZH2. Thus, epigenetic silenc-
ing of BLIMP1 may represent an important mechanism through 
which EZH2 supports lymphoma growth.
In conclusion, our data indicate that EZH2 methyltransferase 
activity is strictly required for the establishment of a protective 
long-term B cell adaptive immune response. EZH2 accomplishes 
this function through the coordinated regulation of GC B cell 
differentiation, proliferation, and response to genotoxic dam-
age imposed by AID. Conversely, enforced BLIMP1 repression, 
coupled to protection against AID mutagenesis, acceleration of 
S-phase entry, and support for BCL6 function, may represent the 
mechanism through which constitutively active EZH2 contributes 
to lymphomagenesis. These results provide a rationale for use of 
EZH2 inhibitors (35–37) in combination with inducers of termi-
nal differentiation, such as IL-21 (55, 56) and genotoxic agents, 
in the treatment of GC-derived DLBCL and follicular lymphoma.
Methods
Mice. Ezh2fl, R26-yfp, Cr2-cre, Cγ1-cre, Cdkn2a–/–, Eμ-BCL2, Aicda–/–, and 
IμHABCL6 mice were previously described (11–13, 28, 57–60). Compound 
mutants were backcrossed to C57BL/6J mice for 6 or more generations and 
kept under specific pathogen–free conditions. Eight- to sixteen-week-old 
mice were immunized by intraperitoneal injection of alum-precipitated NP-
CGG25-36 (100 μg per mouse; Biosearch Technologies) or NP-CGG25/PBS 
(50 μg per mouse) for secondary responses. Sheep red blood cells (1 × 108 cells 
per mouse; Oxoid) were resuspended in PBS and injected intraperitoneally.
Antibodies. Flow cytometry was performed using fluorescent- or biotin-
labeled antibodies reactive to mouse CD19 (1D3; eBioscience), CD21 
(8D9; eBioscience), CD23 (B3B4; eBioscience), CD38 (90; eBioscience), IgD 
(11.26; eBioscience), CD184 (2B11; eBioscience), CD95 (Jo2; BD Biosci-
ences), CD138 (281-2; BD Biosciences), IgG1 (A85-1; BD Biosciences), IgM 
(R33.24.12; K. Rajewsky, Max Delbrück Center for Molecular Medicine, 
Berlin, Germany), CD45R/B220 (RA3-6B2; K. Rajewsky), and Igκ (R33-18-
10; K. Rajewsky). Antibodies against human MHC class II and CD138 were 
provided by S. Cenci (San Raffaele Scientific Institute). NP binding was 
assessed using NIP-BSA conjugated to allophycocyanin (provided by M. 
Hikida, Kyoto University, Kyoto, Japan and T. Takemori, RIKEN, Yokoha-
ma, Japan). PNA was from Vector Laboratories. For intracellular stainings, 
B cells where fixed, permeabilized in Cytofix/Cytoperm (BD Biosciences), 
and stained with IRF4-specific (3E4; BioLegend), H3K27me3-specific 
research article
 The Journal of Clinical Investigation   http://www.jci.org   Volume 123   Number 12   December 2013 5021
P values equal to or lower than 0.05 were considered indicative of sig-
nificance. These P values were FDR corrected for multiple comparisons 
throughout the analysis, with the exception of the identification of enriched 
chromatin domains (for which much stricter thresholds were applied).
Study approval. Animal experimentation was approved by the IFOM Ani-
mal Care Committee (IACUC) and the Italian Ministry of Health.
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were stained with rat anti-mouse IgD (BD Biosciences) and biotin-conju-
gated PNA (Vector Laboratories), followed by rabbit anti-rat Ig coupled to 
horseradish peroxidase. Sections were washed, and streptavidin complex 
(Vector Laboratories) was added. Stains were developed with 3,3 diamino-
benzidine tetrahydrochloride to reveal horseradish peroxidase–conjugated 
antibodies and fast blue for biotinylated PNA. Slides were mounted with 
Immunomount (Thermo) and analyzed with a Leitz Wetzlar Dialux micro-
scope. Photographs were taken with a Leica DM6000 microscope.
ChIP. B cells were fixed in 1% (vol/vol) PBS/formaldehyde, and the reac-
tion was stopped by adding 0.125 M glycine. Fixed cells were harvested 
by centrifugation, washed in PBS, and resuspended in lysis buffer (0.5% 
SDS, 50 mM Tris-HCl, 5 mM EDTA, 100 mM NaCl, and 0.02%NaN3) 
containing 1 mM PMSF and 0.1% (vol/vol) protease inhibitor mixture 
(Sigma-Aldrich). 40 μg sonicated chromatin was immunoprecipitated 
with 3.5 to 5 μg of antibodies specific for H3 (ab1791; Abcam), H3K27me3 
(C36B11; Cell Signaling), and H3K4Me3 (04-745; Millipore) or an IgG con-
trol (ab37415; Abcam). Antibodies (3.5–5 μg) specific for SUZ12 (D39F6; 
Cell Signaling) or RNA polymerase-II (ab5131; Abcam) or an IgG control 
(ab37415; Abcam) were used to immunoprecipitate 500 μg chromatin. 
Antibody-bound DNA was reverse cross-linked, purified, and assayed in 
triplicate by real-time PCR using primers listed in Supplemental Table 3. 
ChIP-seq analysis was performed in duplicate on GC B cells sorted from 
pools of C57BL/6 mice immunized with SRBC. 10 ng sonicated chromatin 
before (input) and after immunoprecipitation with antibodies specific for 
H3K27me3 (C36B11; Cell Signaling) and H3K4me3 (MC315; Millipore) 
was processed with the Illumina ChIP-Seq Sample Prep and Multiplexing 
Oligonucleotide Kits. DNA libraries were quantified and used for cluster 
generation and sequencing on a HiSeq 2000 instrument (Illumina) follow-
ing the manufacturer’s protocol. ChIP-seq raw data have been deposited in 
the Gene Expression Omnibus database (GSE50912). Bioinformatic analy-
ses of ChIP-seq data are described in the Supplemental Methods.
Statistics. Statistical analyses were done by 2-tailed unpaired Student’s t test, 
except for gene expression data using TaqMan Array Cards, for which a non-
parametric Wilcoxon rank-sum test was applied. Fisher’s exact test was used 
to assess the enrichment of H3K27me3 targets within specific gene lists. 
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